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U nited States-Japan Cooperative Cancer Research Program: Melanoma and Skin Cancer-Biology and Comparative Features in the United States and Japan was held from November 13 to November 15, 1987, at the International Lecture Hall, Na­
tional Cancer Center in Tokyo, Japan. This seminar was supported 
by the Japanese Society for Promotion of Science and the National 
Cancer Institute of the U.S. Nine participators from the United 
States, 20 from Japan, and one from the United Kingdom were 
involved. Besides these members, Dr. Robert W. Miller, National 
Cancer Institute, Bethesda, and Dr. Haruo Sugano, Cancer Insti­
tute, Tokyo, attended the entire meeting as the coordinators of the 
program. Other participators included 25 preregistered discussants. 
OVERALL PROGRAM 
A seminar reception was held on November 12, 1987, the night 
before the seminar, in the Togeki Sky Salon "Escargot" where 
approximately 50 people gathered and spent a pleasant evening 
meeting each other. The seminar started at 9:00 a.m., November 
13, with introductory remarks by Dr. Atsuhi Kukita, Dr. Thomas 
B. Fitzpatrick, and Dr. Robert W. Miller. They stressed the impor­
tance of having the meeting, not only with two specific nations 
where the incidence, clinical types, course, and histopathologic 
types of melanoma are different, but also with the medical scientists 
and basic scientists who are worldwide leaders in their individual 
fields. The seminar dinner was held on November 14, with the 
honorable attendance of Prince Masahito and Princess Hanako. 
The summation and closing remarks were made by Dr. Michael 
Wick, Dr. Kowichi Jimbow, and Dr. Haruo Sugano. Dr. Wick 
elegantly and concisely summarized the scientific merits of the 
whole meeting. Dr. Jimbow stressed the importance of medical 
collaboration between basic scientists and medical scientists in the 
study of malignant melanoma for the future in the United States and 
Japan. Dr. Sugano remarked on the important contributions of basic 
and clinical sciences in the field of dermatology by introducing Dr. 
M. Ota as an example of a best clinician, a best scientist, and a best 
man of letters in the field of dermatology in Japan. 
SCIENTIFIC SESSIONS 
The seminar was organized along multidisciplinary lines ranging 
from a study of the pigment cells of fish to human melanoma cells 
and clinical aspects. Specifically, topics were presented in the fol-
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lowing five categories: i) epidemiology and comparative aspects, ii) 
the cellular and basic biology of melanoma, iii) pathogenesis, iv) 
biology of precursor lesions and early diagnosis, and v) methods of 
control and treatment. 
Epidemiology and Comparative Aspects Clues to the patho­
genesis of diseases can sometimes be found by comparing popula­
tions in which the disease is relatively rare with populations in 
which there is a high incidence. Dr. M. A. Tucker summarized the 
recent incidence rates of cutaneous malignant melanoma in three 
geographic locations (Table I). 
She stressed that a) major host susceptibility factor is positive if 
there is a family history of melanoma; and b) if a family member has 
dysplastic nevi, he or she has an approximately 100% lifetime risk of 
melanoma. 
Dr. Kukita and Dr. S. Ikeda implicated the unique location of the 
melanoma and nevi in the Japanese vs whites in the United States: in 
the pigmented races including black races, many melanomas occur 
on the unexposed areas, i.e., soles of the feet, whereas they are more 
commonly seen in the sun-exposed areas, e.g., upper back, in 
whites. Among the main arguments in terms of this racial difference 
are the following: 1) a remarkably low incidence of a high-risk 
group, i.e., patients with a family history of dysplastic melanocytic 
nevi, in the Japanese (Elder, Tucker, Fitzpatrick, and Jimbow); 2) a 
remarkably low incidence of familial malignant melanoma in the 
Japanese (Tucker, Miller); 3) low incidence of melanoma in the 
Japanese may be related to one or more of the following factors: a 
better DNA repair system (Fitzpatrick, Takebe, Carter), a better 
immune-surveillance mechanism (Tucker), age factor related to the 
exposure of children before a certain age, susceptibility of individ­
uals to melanoma (Elwood). 
It became clear that a low incidence of dysplastic melanocytic 
nevi (dysplastic nevus syndrome) in Japan vs a very high incidence 
of this syndrome in the United States may actually correlate well 
with the different incidence of melanoma in Japan and the United 
States. 
Dr. Fitzpatrick and Dr. A. Sober proposed the necessity of public 
education for the early recognition of malignant melanoma. Fi­
nally, Dr. Elwood showed the natural history of cutaneous mela­
noma of individuals living in North America, Australia, and Eu­
rope. He also emphasized early diagnosis using professional and 
public education approaches. Identification of high-risk individ­
uals, followed by early diagnosis or prevention by removal of pre­
cancerous lesions, is valuable for extremely high-risk groups. 
The Cellular and Basic Biology of Melanoma This session 
was designed to clarify the regulatory factors responsible for prolif­
eration and differentiation of cells in the epidermis, and to define 
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Table I. Incidence Rates/100,OOO/Year 
\1ale 
i'emale 
Osaka, Japan 
0.2 
0.2 
Seer, U.S.A. 
6.5 
6.3 
New South Wales, Australia 
15.2 
19.1 
the factors that might be relevant to prevention of skin cancer and 
melanoma. 
First, Dr. S. Ito introduced a new method to quantitate the uri­
nary melanogen, i.e., O-methyl derivatives of 5,6-dihydroxyindole 
and 5,6-dihydroxyindole-2-carboxylic acid. By this method, his 
research group was able to measure a 10- to 100-fold increase in the 
urinary excretion of "melanogene" in melanoma-bearing mice, as 
compared with normal C57BL mice. The question was raised 
whether such an excretion of urinary melanogen correlates with the 
content of eu/pheomelanin in melanoma tissue (Mishima, Jim­
bow). This analysis would provide, in the future, new information 
regarding the nature of the mixed content of eu/pheomelanin in 
melanoma tissues (Wick). 
Tyrosinase is the enzyme responsible for the formation of mela­
nin. Dr. T. Takeuchi, using an organ culture method and special 
substrains of mice (lethal yellow mice and recessive yellow mice), 
compared the biologic effect of DbcAMP and aMSH. Significantly, 
through this study, his research group has succeeded in defining the 
genetic control of the tyrosinase molecule for differentiation of 
pigment cells in hair follicles. The information provided is the first 
study to clarify the nature of the tyrosinase gene in "normal" tissue 
(Fitzpatrick). The biologic role of DbcAMP and aMSH to pigment 
cells was also tested in cultured goldfish by Dr. J. Matsumoto to 
clarify acquisition of phenotypic instability upon neoplastic trans­
formation and the possible relationship between the stages of cyto­
differentiation and susceptibility for neoplastic transformation. 
Dr. M. Mihm contrasted the biologic characteristics of melanoma 
in Japanese cases based on his own review of 83 cases of melanoma 
and nevi in Japanese. He emphasized the importance of the histol­
ogy of the acral lentiginous melanoma in situ depending on the 
anatomic regions affected by the neoplasm. Dr. Mihm also defined a 
subtle histologic change that would be the first sign in the develop­
ment of melanoma in situ. 
Dr. T. Kuroki introduced a new technique of explant outgrowth 
culture of pigment cells by which he could demonstrate a defect in 
UV-induced unscheduled DNA synthesis (UVS) in epidermal cells 
of xeroderma pigmentosum and binding and action of EGF and 
TP A on epidermal cells. He found, in contrast to pigment cells, 
essentially negative responses to TP A on epidermal cells. 
Research groups headed by Dr. Y. Ishibashi and T. Hirone char­
acterized a certain aspect in the nature of the precancerous condition 
in skin tumors. Dr. Ishibashi measured nuclear DNA content of 
epidermal cells for prokaryotic lesions using microfluorometry ap­
plied directly on paraffin sections. In contrast, Dr. Hirone and his 
associates showed a loss or reduction in the expression of antigen 
properties in melanoma tissues using various forms of polyclonal 
and monoclonal antibodies. 
Pathogenesis In this session, three major topics were discussed: 1) 
pigment cells and tumors in fish, 2) sun exposure and DNA damage, 
and 3) immunology and oncogenes in melanoma. Prince Masahito, 
Dr. T. Ishikawa, and Dr. Sugano demonstrated how the neural crest 
cells differentiate into pigment cells of fish, i.e., melanophores, 
erythrophores, and iridophores, and how these cells, when trans­
formed, can be characterized, in addition to conventional histopath­
ologic studies for the genetic/oncogenic expressions. In addition, 
Prince Masahito emphasized not only the fine structure of the pig­
ment cells, but also transforming genes (ras gene) of the tumors. 
Several questions were raised regarding the nature of fish tumors; 
one of these questions was the difference in the site of point muta­
tion to activate the ras gene (Wick and Carter). Following Prince 
Masahito's presentation, another topic of fish tumors was presented 
by Dr. I. Kimura, who reported on how environmental factors can 
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activate or develop certain forms of pigmented tumors in fish. Dr. 
Kimura has shown that Nibe mitsukurii, feral fish inhabiting the 
shallow waters, produce pigmented tumors which probably reflect 
environmental pollution by carcinogens such as nifurpirinol, 
N -meth y 1-N' -nitro-N -nitrosoguanidine or 7, 12-dimeth y Iben­
zanthracene. Removal of contaminated sediments from Kumano 
liver had reduced the incidence of tumors in Nibe fish at rates 
ranging from 40%-50% (1983) to 20% ( 1986). 
Most of the U.S. participants were not familiar with the papers by 
Prince Masahito and Dr. Kimura. However, they indeed captured 
the interest of the attendants, and the two talks were highlights of 
this seminar, eliciting many questions. Among the questions asked 
were why the fish Nibe produced such a high incidence of pig­
mented tumors and how the incidence was so selective to pigmented 
tumors (Fitzpatrick, Mihm, Sober, Tucker, and Elder). 
Dr. Carter and Dr. Ishikawa discussed DNA damage in skin 
cancer after exposure to ultraviolet (UV) irradiation. Dr. Carter 
stressed that chronic exposure to UV irradiation and a high total 
cumulative dose may be less deleterious than periodic bursts of large 
amounts of sun exposure that lead to severe sunburn. He also 
stressed that damage that is apt to be most cytotoxic is probably less 
effective as an inducer of skin cancer than more-subtle damage, 
which is tolerated but can initiate malignant transformation. Dr. 
Ishikawa, using polyclonal antibodies raised against DNA modified 
with carcinogen 4-hydroxyaminoquinoline I-oxide or benzopy­
rene, succeeded in locating in situ DNA adducts on paraffin-embed­
ded sections. He stressed that the intensity of staining correlates well 
with the level of unscheduled DNA synthesis. In answering several 
questions, he said that aged mice are deficient in DNA repair after 
UV exposure, and that intermittent UV exposure is carcinogenic to 
the melanocytes. Dr. Takebe and Dr. A. Oikawa discussed the na­
ture of melanoma and other skin cancers in xeroderma pigmento­
sum (XP) patients. Dr. Takebe demonstrated several unique features 
of Japanese XP patients: a) 12% of skin cancers in Japanese patients 
with XP were malignant melanoma; b) their histopathologic sub­
type was lentigo malignant melanoma, while in U.S. patients with 
XP melanomas were mostly the superficial spreading subtype. He 
also indicated that the minimum age of melanoma development was 
three years, many patients being five years of age, and that eye 
melanoma can occur in XP patients, e.g., in one male it occurred at 
the age of 20. Dr. Oikawa presented a paper that was different from 
the one shown in the abstract. He discussed the response of unsched­
uled DNA synthesis (UDS) induced by UV irradiation in patients 
suffering from XP and showed that UDS-proficient XP cells reveal 
several unique responses to treatment with caffeine after UV irra­
diation: i) caffeine enhanced UV -induced sister chromatid ex­
change (SCE) dose-dependently and synergistically; ii) the en­
hanced SCE was not reduced by holding cells in a growth-arrested 
state; and iii) the SCE causing damage was retained in excision-pro­
ficient XP cells. 
Immunologic aspects of malignant melanoma were discussed by 
Dr. J.c. Bystryn and Dr. M. Taniguchi. Dr. Bystryn discussed im­
munosurveillance and melanoma. He first showed the marked and 
specific increase in resistance to melanoma in animals (e.g., chim­
panzee) by immunization to melanoma vaccines, and then empha­
sized that the vaccines can help subjects in melanoma-prone families 
or patients with dysplastic melanocytic nevi. Some of these mela­
noma vaccines are ready for control study. Dr. M. Tagawa and Dr. 
Taniguchi discussed the genomic cloning of DNA controlling ex­
pression of mouse melanoma antigen and transforming activity. 
They showed that pD2 (34.8 Kb) expresses M56 mouse melanoma 
determinants in human melanoma and possesses the transforming 
activity in NIH/3T3 cells. 
Finally, Dr. T. Sekiya discussed the oncogenes in pigment cell 
neoplasms in general. He found transforming activity in one of the 
melanoma cell lines, SK2 maintained in nude mice. The transform­
ing gene was activated by a single point mutation at cordon 6 1  in the 
second axon. He further indicated that amplification of the C-H­
ras-l aile, in addition to the point of mutation, may play a role in the 
development of the tumor. Questions raised included whether 
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DNA changes specific to primary melanoma; whether it can be seen 
in other pigmented tumors, e.g., pigmented melanocytic nevi and 
dysplastic melanocytic nevi; and whether loss of chromosome 3 can 
also be seen in other tumors. These questions must be answered in 
the future. 
Biology of Precursor Lesions and Early Diagnosis In this 
session the nature and significance of dysplastic melanocytic nevi 
and giant melanocytic nevi were discussed. Dr. Elder first summa­
rized concisely the present status of dysplastic melanocytic nevi, 
e.g., clinical features, histopathologic diagnosis, and relationship to 
the development of malignant melanoma. He indicated that a use­
ful, simple, clinical classification is divided into two categories: 1) 
high risk-dysplastic melanocytic nevi (DMN) with a personal or 
family history of malignant melanoma; and 2) low risk-no mela­
noma history. Clinical management should reflect this risk hetero­
geneity and should consist of patient education, periodic follow-up 
at intervals dependent on risk, and excision biopsy of lesions suspi­
cious for malignant melanoma. He also indicated that future re­
search should aim to define the significance of DMN as markers by 
means of epidemiologic case control and cohort studies, and as pre­
cursors by means of laboratory investigation of the mechanisms of 
tumor progression and the factors that promote or inhibit it. Dr. 
Jimbow then demonstrated the clinical features and characteristics 
of Japanese patients with DMN and their fine structural and im­
munohistochemical properties. Reports of DMN have increased in 
number in recent Japanese literature. Most of these cases, however, 
belong to a solitary, sporadic form, and only two of them appear to 
be familiar and/or associated with malignant melanoma. Although 
he did not specifically give an answer regarding the two questions of 
why such a low incidence of DMN occurs in the Japanese and why 
the incidence of DMN is high in white patients, the new methodol­
ogy he brought about was the fine structural and immunohisto­
chemical properties of DMN that were characterized by utilizing 
the monoclonal antibodies, MoAb HMSA. By demonstrating anti­
gen protein reacting with MoAb HMSA, he could identify dysplas­
tic melanocytes in situ on routine paraffin sections. It was also em­
phasized that the fine structural changes in synthesis and 
melanization of melanosomes appear to be unique to DMN; they 
may fill the gap of abnormal melanogenesis existing between cuta­
neous malignant melanoma and common melanocytic nevus. 
Unique clinical features of giant pigment melanocytic nevus and 
malignant melanoma in Japan were demonstrated by Y. Hori and T. 
Arao. Dr. Hori first demonstrated the frequency with which giant 
pigmented melanocytic nevi progress to malignant melanoma. In 
the literature, it was estimated to be 2% -31 %; Lorentzen et al 
( 1977) estimated a lifetime risk of malignant transformation of 
giant melanocytic nevi to be 4.6%, and Rhodes et al ( 1981) esti­
mated it to be at least 6.3%. Dr. Hori also spoke of his experience 
with cases of congenital giant pigment melanocytic nevi that devel­
oped into malignant melanoma after abrasion of the nevi. Histo­
pathologic and ultrastructural studies of nonmalignant nodules in 
giant nevi revealed that nevi cells were atypical and contained ab­
normal melanosomes. Dr. Arao showed an unusual case of a 32-
year-old Japanese female who suffered from a giant pedunculate, 
heavily pigmented tumor occurring on the external genitalia. 
Methods of Control and Treatment The aim of this session was 
first to summarize the clinical features of melanoma and skin cancer 
in the United States and Japan; second, to discuss the results of the 
treatment currently being used in both the United States and Japan; 
and third, to study the possibilities for development of rational and 
experimental approaches in the therapy. Dr. Sober compared the 
clinical characteristics of skin cancer and melanoma in Japanese and 
U.S. populations and defined the clinical and histopathologic fea­
tures that are unique to melanoma found in the two groups. He 
emphasized that the ability to predict the outcome for an individual 
patient with melanoma is important not only to the prognostic 
interests of the particular patient involved but also to the design and 
interpretation of surgical and adjuvant therapy studies. He also 
stressed the importance of teaching for the general practitioners and 
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subspecialties of medicine to detect early lesions of malignant mela­
noma. Questions brought about in his talk included whether the 
level of invasion or the thickness of the primary tumor is a more-ac­
curate prognostic sign for malignant melanoma. His answer was 
that the tumor thickness is a much better indication than level of 
invasion for estimating the prognosis of malignant melanoma. 
Dr. K. Ishihara summarized the present status of melanoma treat­
ment by interferon, interleukin-2, and other biologic response mod­
ifiers (BRM). In Japan many BRM have been applied, in addition to 
chemotherapy of malignant melanoma. These include interferon 
(IFN), interleukin-2 (IL-2), tumor necrosis factor (TNF) , living 
BCG, MY-I, WPG (CWS of Bifidobacterium bifidum), OK-432 
(Picibanil, originating hemolytic streptococci), bestatin, forpfeni­
cinol, etc. Among IFN-a, -P and y, IFN-P showed better results for 
the treatment of melanoma than IFN-a. Prolongation of survival 
time by the administration of IFN-pwas observed. His opinion was 
that efficacy of IFN-y appears to be lower than IFN-a and -po 
Dr. DuPont Guerry discussed the immune-based therapy of ma­
lignant melanoma. He summarized the current approaches to the 
therapy of melanoma using immune-based tactics in the following 
ways: 1) nonspecific immune stimulation (e.g., with microbial 
products) or suppression of "suppressor" mechanisms (e.g., with 
low-dose cyclophosphamide); 2) "active" vaccination with autolo­
gous or allogeneic tumor cells, tumor-associated antigens, and anti­
idiotypic antibodies; 3) "passive" therapy with naked or adorned 
monoclonal antibodies of at least relative specificity for melanoma; 
4) the use of a heterogeneous group of BRM comprised of various 
cytokines including the interferons, interleukin-2, and tumor ne­
crosis factor; and 5) autologous cellular therapy with lymphokine­
activated killer (LAK) cells or tumor infiltrating lymphocytes 
(TIL). 
The current knowledge of the experimental chemotherapy for 
malignant melanoma was discussed by Dr. Wick and Dr. Mishima. 
Dr. Wick first introduced the reducing agent as the controller of 
replication in malignant melanoma. The rationale for carrying out 
this approach of selective chemotherapy relies on unique cellular 
target; nonessential function to host; nontoxicity; and complemen­
tary action with conventional agents (differentiation vs gross). He 
also introduced a new experimental chemotherapeutic agent, i.e., 
3,4-dihydroxybenzylamine, by which he found a marked inhibition 
of melanoma cells in vitro and in vivo (growth inhibition being 
70% in 3,4-dihydroxybenzylamine and 48% in dopamine). He also 
indicated that this new agent can be a project for the phase I clinical 
study. 
As the last topic of this session, Dr. Mishima discussed selective 
thermal neutron capture therapy and diagnosis of malignant mela­
noma using its specific metabolic activity. The new compound 
which he introduced is IOBI-BPA. After introducing the theory and 
rationale of this chemoradiotherapeutic agent, he showed the suffi­
cient lOB accumulation in inoperable human melanoma lesion and 
its disappearance by a la-min neutron irradiation. He also indicated 
the possibility of performing successfully the first clinical trial. 
SEMINAR SUMMARY 
Malignant melanoma has now become a major international health 
problem, affecting all nations with increasing incidence and mortal­
ity. It may be epidemic in the western world and of increasing 
importance in the eastern countries. The foremost basic biology in 
both melanoma and nonmelanoma skin cancer has been carried out 
primarily by Japanese and U.S. scientists. The present conference 
involving these two nations has therefore brought together leaders 
in the field from both countries and has provided a new level of 
communication that serves to enhance progress in this significant 
area. During this seminar, recent advances regarding the contribu­
tion of basic knowledge of normal melanocytes to the study of 
melanoma and oncogene structure, function, immunology of ma­
lignant melanoma, as well as new therapeutic modalities, have been 
discussed for their potential application to malignant melanoma. 
Special scientific advantages to better clinical management in Japan 
and the United States resulting from this meeting include increased 
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communication among the investigators and establishment of col­
laborative efforts between the Japanese and U.S. investigators at­
tending this seminar. This development of mutual collaboration 
should greatly increase the pace at which fundamental basic obser­
vations are being made, as well as their potential application to 
clinical progress. 
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